

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Morphosys AGApplication No./Patent No.: 10/602,141 Filed/Issue Date: June 23, 2003Entitled: Serum protein-associated target-specific ligands and identification method thereforMorphosys AG, a Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest
(The extent (by percentage) of its ownership interest is _____ %)

in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy therefore is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Inventors To: Dyax Corp.

The document was recorded in the United States Patent and Trademark Office at
Reel 014171, Frame 0024, or for which a copy thereof is attached.

2. From: Dyax Corp. To: Morphosys AG

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (*i.e.*, a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

/Laurie Butler Lawrence/

Signature

October 7, 2008

Date

Laurie Butler Lawrence

Printed or Typed Name

617-395-7000

Telephone Number

Patent Attorney

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

ASSIGNMENT

For valuable consideration, DYAX CORP., a corporation of Delaware having a place of business at 300 Technology Square - 8th Floor, Cambridge MA 02139; and its successors and assigns (collectively hereinafter called "the Assignor"); hereby assigns to MORPHOSYS AG, a company created and existing under the laws of Germany, and having a place of business at Lena-Christ-Str. 48, Martinsried, Germany 82152, and its successors and assigns (collectively hereinafter called "the Assignee"), the entire right, title and interest throughout the world in the inventions and improvements which are subject of patents and patent applications listed on Schedule A and including said patents, applications, and any and all continuations, continuations-in-part, and divisional applications, and any and all United States and foreign patents (including reissues, reexaminations, extensions), utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing dates of said applications under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and Assignor hereby declares its acceptance of said assignment.

In witness whereof, Assignor has caused this Assignment to be signed in its corporate name by its duly authorized officers.

DYAX CORP.

DATE: 8/19/08

Ivana Magovcovic Liebisch
(signature)

Name: Ivana Magovcovic Liebisch, Ph.D., J.D.
Executive Vice President of Administration
Title: and General Counsel

STATE OF Massachusetts,
COUNTY OF Middlesex) SS.


On August 19, 2008, before me, the undersigned, a notary public for the State of Massachusetts, there personally appeared Ivana Magovcovic Liebisch personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to this Assignment, who acknowledged having executed the same in his authorized capacity and that by his signature on this Assignment, the person or the entity upon behalf of which he acted, executed this Assignment.


WITNESS my hand and official seal.

Deborah L. Perates
Notary Public

Deborah L. Perates
NOTARY PUBLIC
My commission expires Nov. 6, 2009

MORPHOSYS AG



(signature)




Name: Bernd Hutter Stephan S. Yoder

Title: Sr. Manager Licensing & IP General Counsel

Witnessed by:

Name: 
Virginie Galtschke, Counsel

Date: 19. Sept. 08

Name: 
Sylvia Fischer,

Date: 19. Sept 08

SCHEDULE A

<u>CLIENT</u> <u>#</u>	<u>APPLICATION</u> <u>NUMBER</u>	<u>TITLE</u>	<u>PUBLICATION</u> <u>NUMBER</u>	<u>PATENT</u> <u>NUMBER</u>	<u>ISSUE</u> <u>DATE</u>	<u>FILE</u> <u>DATE</u>
AUSTRIA						
073AT1	97918488.4	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)		904541	10/6/2004	3/20/1997
AUSTRIA ✓						
AUSTRALIA						
073AU1	26583/97	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)		715,608	5/18/2000	3/20/1997
105AU1	2002335930	SERUM ALBUMIN BINDING MOIETIES	US 2002335930	2002335930	11/17/2005	3/8/2002
058AU1	PCT/US03/19902	SERUM PROTEIN- ASSOCIATED TARGET- SPECIFIC LIGANDS AND IDENTIFICATION METHOD THEREFOR				6/23/2003
AUSTRALIA ✓						
BELGIUM						
073BE1	97918488.4	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)		904541	10/6/2004	3/20/1997
BELGIUM ✓						

SCHEDULE A CONTINUED

<u>CLIENT #</u>	<u>APPLICATION NUMBER</u>	<u>TITLE</u>	<u>PUBLICATION NUMBER</u>	<u>PATENT NUMBER</u>	<u>ISSUE DATE</u>	<u>FILE DATE</u>
CANADA						
073CA1	2248243	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)				3/20/1997
105CA1	2440582	SERUM ALBUMIN BINDING MOIETIES	WO02076489 A1)			3/8/2002
058CA1	2490009	SERUM PROTEIN- ASSOCIATED TARGET- SPECIFIC LIGANDS AND IDENTIFICATION METHOD THEREFOR				6/23/2003
SWITZERLAND						
073CH1	97918488.4	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)		904541	10/6/2004	3/20/1997
CHINA						
073CN1	97194698.1	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)	CN1198837C	ZL97194698.1	5/27/2005	3/20/1997
GERMANY						
073DE1	97918488.4	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)		904541	10/6/2004	3/20/1997

SCHEDULE A CONTINUED

<u>CLIENT</u> <u>#</u>	<u>APPLICATION</u> <u>NUMBER</u>	<u>TITLE</u>	<u>PUBLICATION</u> <u>NUMBER</u>	<u>PATENT</u> <u>NUMBER</u>	<u>ISSUE</u> <u>DATE</u>	<u>FILE</u> <u>DATE</u>
DENMARK						
073DK1	97918488.4	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)		904541	10/6/2004	3/20/1997
EUROPE						
073EP1	97918488.4	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (tPA) [1999/13]	EP0904541	904541	10/6/2004	3/20/1997
105EP1	2753771.1	SERUM ALBUMIN BINDING MOIETIES [2004/02]	EP1377306			3/8/2002
058EP1	3739293.3	SERUM PROTEIN- ASSOCIATED TARGET- SPECIFIC LIGANDS AND IDENTIFICATION METHOD THEREFOR	EP1576172			6/23/2003
SPAIN						
073ES1	97918488.4	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)		904541	10/6/2004	3/20/1997
FINLAND						
073FI1	97918488.4	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)		904541	10/6/2004	3/20/1997

SCHEDULE A CONTINUED

<u>CLIENT</u> <u>#</u>	<u>APPLICATION</u> <u>NUMBER</u>	<u>TITLE</u>	<u>PUBLICATION</u> <u>NUMBER</u>	<u>PATENT</u> <u>NUMBER</u>	<u>ISSUE</u> <u>DATE</u>	<u>FILE</u> <u>DATE</u>
FRANCE						
073FR1	97918488.4	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)		904541	10/6/2004	3/20/1997
GREAT BRITAIN						
073GB1	97918488.4	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)		904541	10/6/2004	3/20/1997
GREECE						
073GR1	97918488.4	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)		904541	10/6/2004	3/20/1997
IRELAND						
073IE1	97918488.4	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)		904541	10/6/2004	3/20/1997
ISRAEL						
073IL1	126,045	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)				3/20/1997
ITALY						
073IT1	97918488.4	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)		904541	10/6/2004	3/20/1997

SCHEDULE A CONTINUED

<u>CLIENT</u> <u>#</u>	<u>APPLICATION</u> <u>NUMBER</u>	<u>TITLE</u>	<u>PUBLICATION</u> <u>NUMBER</u>	<u>PATENT</u> <u>NUMBER</u>	<u>ISSUE</u> <u>DATE</u>	<u>FILE</u> <u>DATE</u>
JAPAN						
073JP1	533677/1997	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)				3/20/1997
105JP1	2002-575002	SERUM ALBUMIN BINDING MOIETIES	2004-535373			3/8/2002
058JP1	2004-516200	SERUM PROTEIN- ASSOCIATED TARGET- SPECIFIC LIGANDS AND IDENTIFICATION METHOD THEREFOR				6/23/2003
LUXEMBOURG						
073LU1	97918488.4	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)		904541	10/6/2004	3/20/1997
MONACO						
073MC1	97918488.4	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA) (See Notes)		904541	10/6/2004	3/20/1997
NETHERLANDS						
073NL1	97918488.4	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)		904541	10/6/2004	3/20/1997

SCHEDULE A CONTINUED

<u>CLIENT</u> <u>#</u>	<u>APPLICATION</u> <u>NUMBER</u>	<u>TITLE</u>	<u>PUBLICATION</u> <u>NUMBER</u>	<u>PATENT</u> <u>NUMBER</u>	<u>ISSUE</u> <u>DATE</u>	<u>FILE</u> <u>DATE</u>
---------------------------	-------------------------------------	--------------	-------------------------------------	--------------------------------	-----------------------------	----------------------------

PATENT COOPERATION TREATY APPLICATIONS

073WO1	PCT/US97/04426	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)	WO97/35197			3/20/1997
105WO1	PCT/US02/07271	SERUM ALBUMIN BINDING MOIETIES	WO02076489			3/8/2002
058WO1	PCT/US03/19902	SERUM PROTEIN- ASSOCIATED TARGET- SPECIFIC LIGANDS AND IDENTIFICATION METHOD THEREFOR	WO04001064			6/23/2003

PORTUGAL

073PT1	97918488.4	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)		904541	10/6/2004	3/20/1997
--------	------------	--	--	--------	-----------	-----------

SWEDEN

073SE1	97918488.4	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)		904541	10/6/2004	3/20/1997
--------	------------	--	--	--------	-----------	-----------

SCHEDULE A CONTINUED

<u>CLIENT #</u>	<u>APPLICATION NUMBER</u>	<u>TITLE</u>	<u>PUBLICATION NUMBER</u>	<u>PATENT NUMBER</u>	<u>ISSUE DATE</u>	<u>FILE DATE</u>
UNITED STATES						
73001	08/821,744	POLYPEPTIDES THAT BIND TO TISSUE PLASMINOGEN ACTIVATOR (TPA)		6,084,062	7/4/2000	3/20/1997
73002	09/497,435	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)		6,462,172	10/8/2002	2/3/2000
73003	10/193,588	PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (TPA)	US 2003- 0162942 A1	7,074,560	7/11/2006	7/11/2002
105P01	60/331,352	SERUM ALBUMIN BINDING MOIETIES				3/9/2001
105P02	60/292,975	SERUM ALBUMIN BINDING MOIETIES				5/23/2001
105001	10/094,401	SERUM ALBUMIN BINDING MOIETIES	US 2003- 0069395 A1	7,211,395	5/1/2007	3/8/2002
058P01	60/390,657	SERUM PROTEIN- ASSOCIATED TARGET-SPECIFIC LIGANDS AND IDENTIFICATION METHOD THEREFOR				6/21/2002
58001	10/602,141	SERUM PROTEIN- ASSOCIATED TARGET-SPECIFIC LIGANDS AND IDENTIFICATION METHOD THEREFOR	US-2004- 0071705-A1			6/23/2003